Glycoform and net charge heterogeneity in gp120 immunogens used in HIV vaccine trials.
<h4>Background</h4>The RV144 clinical trial showed for the first time that vaccination could provide modest but significant protection from HIV-1 infection. To understand the protective response, and to improve upon the vaccine's efficacy, it is important to define the structure of...
Enregistré dans:
| Auteurs principaux: | , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Public Library of Science (PLoS)
2012
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/34b4ba247fa246ce969cefb256a8b7db |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|